You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for NS 11021
NS 11021 is an activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1). Exhibits no modulatory effect on a variety of K+ (KV), Na+ and Ca2+ currents at concentrations <10 μM. Alters gating kinetics, but does not affect single channel conductance. Shown to bind BKCa in open and closed conformations; thought to bind the α subunit.
Compound Libraries for NS 11021
Technical Data for NS 11021
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for NS 11021
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for NS 11021
The following data is based on the product molecular weight 511.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.96 mL||9.78 mL||19.56 mL|
|5 mM||0.39 mL||1.96 mL||3.91 mL|
|10 mM||0.2 mL||0.98 mL||1.96 mL|
|50 mM||0.04 mL||0.2 mL||0.39 mL|
References for NS 11021
References are publications that support the biological activity of the product.
Layne et al (2009) BK channel activation by NS11021 decreases excitability and contractility of urinary bladder smooth muscle. Am.J.Physiol.Regul.Integr.Comp.Physiol. 298 R378 PMID: 19923353
Bentzen et al (2007) The small molecule NS11021 is a potent and specific activator of Ca2+-activated big-conductance K+ channels. Mol.Pharmacol. 72 1033 PMID: 17636045
Kun et al (2009) NS11021, a novel opener of large-conductance Ca2+-activated K+ channels, enhances erectile responses in rats. Br.J.Pharmacol. 158 1465 PMID: 19845682
If you know of a relevant reference for NS 11021, please let us know.
View Related Products by Product Action
Keywords: NS 11021, NS 11021 supplier, NS11021, NS_11021, BKCa, KCa1.1, large-conductance, Ca2+-activated, Ca2+-dependent, calcium, potassium, K+, channels, activators, activates, openers, opens, Ca2+-Activated, Potassium, Channels, 4788, Tocris Bioscience
1 Citation for NS 11021
Citations are publications that use Tocris products. Selected citations for NS 11021 include:
Bellono (2017) Molecular basis of ancestral vertebrate electroreception. Nature 543 391 PMID: 28264196
Do you know of a great paper that uses NS 11021 from Tocris? Please let us know.
Reviews for NS 11021
Average Rating: 5 (Based on 2 Reviews.)
Have you used NS 11021?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
The following concentrations we were used:1 μM Bay K, 10 μM nifedipine, 10 μM nimodipine, 300 nM omega -agatoxin, 1 μM omega -conotoxin, 5 μM mibefradil, 1 μM tetrodotoxin, 1 μM charybdotoxin, 100 nM iberiotoxin, 10 μM NS11021.
NS 11021 was used as a standard BK channel opener as it is an activator of large-conductance Ca2+-activated potassium channels (BKCa, KCa1.1). It performed well under lab conditions. Needs to be dissolved in organic solvent, ethanol and DMSO are good options for that.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.